Swiss chemical firm EMS-Chemie reported a 5.2% increase in net operating income for 2025, reaching CHF 567 million. Despite this growth, sales dipped 5.8% to CHF 1.95 billion, largely due to unfavorable currency effects. The company's EBIT margin expanded to 29.1%. However, shares fell 3% after the company warned of further sales declines this year.

EMS-Chemie's performance reflects the challenges faced by European exporters amid a strong Swiss franc and global economic uncertainty. While the company saw margin improvements and increased profitability, currency headwinds are impacting revenue. Investors are reacting to the projected sales decline and the potential impact on future earnings. The company is actively working to mitigate trade barriers.

For 2026, EMS expects net sales below 2025 levels but net operating income slightly above. The board proposed higher dividends. Analysts at Kepler Cheuvreux do not anticipate major earnings revisions. The company's focus on new business and supply chain adjustments to avoid trade barriers demonstrates its efforts to maintain performance.

EMS-Chemie's expansion into robotics and automotive applications, including energy-efficient manufacturing processes, showcases its commitment to innovation. The firm's ability to navigate trade conflicts and a strong Swiss franc is essential for its future success. Investors will watch for how the company manages currency risks and maintains profitability.